APOL1 and chronic kidney disease: SuPAR acts as a tripartite complex of suPAR, APOL1 risk variants, and αvβ3 integrin on podocytes, resulting in podocyte foot process effacement, disrupted glomerular barrier function, proteinuria, and thereby chronic kidney disease [44].